Oncology – Breast
M-A | Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials
9 Feb, 2023 | 13:37h | UTC
Cohort Study | Risk of primary hematologic cancers following incident non-metastatic breast cancer
8 Feb, 2023 | 12:11h | UTC
M-A | Risk of second primary cancer among breast cancer patients
6 Feb, 2023 | 13:10h | UTC
SR | Partial breast irradiation for breast cancer
3 Feb, 2023 | 14:06h | UTCPartial Breast Irradiation for Breast Cancer – Agency for Healthcare Research and Quality
SR | Immediate breast reconstruction uptake in older women with primary breast cancer
1 Feb, 2023 | 13:04h | UTC
Perspective | Endocrine treatment for 5 years or radiation for 5 days for patients with early breast cancer older than 65 years
26 Jan, 2023 | 12:04h | UTC
Commentary from the author on Twitter
?Hot off the press @JCO_ASCO: For decades we have been offering RT omission for early #bcsm patients, here we discuss how tides have changed and its time to omit hormonal therapy and treat with RT instead @TaghianAlphonse @MGHBreastOnc @LurieCancer
— George E. Naoum, MD, MMSCI (@George_E_Naoum) December 20, 2022
RCT | Breast-cancer–related lymphedema after reverse lymphatic mapping and selective axillary dissection vs. standard surgical treatment of axilla
24 Jan, 2023 | 14:15h | UTC
Commentary on Twitter
New & available #OpenAccess | Occurrence of breast-cancer–related #lymphedema after reverse lymphatic mapping and selective axillary dissection versus standard surgical treatment of axilla: A two-arm randomized clinical trial https://t.co/fXB7PfysCH @OncoAlert pic.twitter.com/wWNhC9BMvY
— ACS Journal Cancer (@JournalCancer) October 20, 2022
RCT | Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer
20 Jan, 2023 | 14:20h | UTCAbemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentaries:
Interim Analysis of Overall Survival in the monarchE Trial – The ASCO Post
Commentary on Twitter
?Adjuvant abemaciclib reduces the risk of recurrence in patients with hormone receptor (+), HER2(-), node-positive, high-risk early #BreastCancer
?Serious AEs 15·5%
?Most common G 3–4 AE neutropenia 19·6%@OncoAlert @SABCSSanAntonio #SABCS #SABCS2022 https://t.co/KY2NskvB9B pic.twitter.com/2uauz6hPlO— Yüksel Ürün (@DrYukselUrun) December 6, 2022
Review | Role of immunotherapy in breast cancer
18 Jan, 2023 | 14:03h | UTCRole of Immunotherapy in Breast Cancer – JCO Oncology Practice
RCT | Cosmetic results and side effects of accelerated partial-breast irradiation vs. whole-breast irradiation for low-risk invasive carcinoma of the breast
15 Jan, 2023 | 19:53h | UTCCosmetic Results and Side Effects of Accelerated Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Carcinoma of the Breast: The Randomized Phase III IRMA Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary from the author on Twitter
5yr results of the phase 3 #IRMAtrial: EBRT #APBI b.i.d. associated with slightly increased rate of moderate soft tissue and bone toxicity and a slightly inferior cosmesis, though overall toxicity was in an acceptable range @JCO_ASCO #BCSM @OncoAlert https://t.co/8LHE2ut3t2
— Bruno Meduri (@brunomeduri) January 9, 2023
ASCO Guideline Update | Chemotherapy and targeted therapy for endocrine-pretreated or hormone receptor–negative metastatic breast cancer
13 Jan, 2023 | 13:28h | UTC
Cohort Study | Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2
13 Jan, 2023 | 13:14h | UTC
Post-trial follow-up | Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer.
15 Dec, 2022 | 13:29h | UTCFluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: Dose-Dense Adjuvant Chemotherapy “Optimal” for High-Risk Early Breast Cancer – Cancer Therapy Advisor
Commentary on Twitter
Online first: end-of-study results from the randomised, phase 3 GIM2 trial: #fluorouracil and dose-dense adjuvant #chemotherapy in patients with #early-stage #breastcancer https://t.co/9YD5w9aLY2 pic.twitter.com/RmPdi37sQB
— The Lancet Oncology (@TheLancetOncol) November 10, 2022
Post-trial follow-up | Radiotherapy vs. surgery of the axilla after a positive sentinel node in breast cancer.
14 Dec, 2022 | 14:42h | UTCRadiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: ART Preferred Over ALND in Sentinel Node-Positive Early Breast Cancer – Cancer Therapy Advisor
RCT | Mepitel film for the prevention of acute radiation dermatitis in breast cancer.
12 Dec, 2022 | 12:40h | UTCMepitel Film for the Prevention of Acute Radiation Dermatitis in Breast Cancer: A Randomized Multicenter Open-Label Phase III Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
RCT | Trastuzumab deruxtecan vs. trastuzumab emtansine in patients with HER2-positive metastatic breast cancer.
8 Dec, 2022 | 12:49h | UTC
Post-trial follow-up | Long-term outcomes of adjuvant denosumab in breast cancer.
22 Nov, 2022 | 13:14h | UTCLong-Term Outcomes of Adjuvant Denosumab in Breast Cancer – NEJM Evidence
Original Study: Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial – The Lancet (link to abstract – $ for full-text)
18F-sodium fluoride PET–CT vs. 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer.
22 Nov, 2022 | 13:09h | UTCIntra-individual comparison of 18F-sodium fluoride PET–CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: 18F-NaF PET-CT More Accurate Than 99mTc-MDP SPECT for Detecting Bone Metastasis – Cancer Therapy Advisor
Cohort Study | Use of breast cancer risk factors may identify risk-adapted starting age of screening.
18 Nov, 2022 | 13:16h | UTCInvited Commentary: Risk-Based Approaches to Breast Cancer Screening in China – JAMA Network Open
Commentary on Twitter
https://twitter.com/JAMANetworkOpen/status/1590766235989708801
Phase 2 RCT | Non-hormonal drug reduces vasomotor symptoms in women taking oral adjuvant endocrine therapy after breast cancer.
15 Nov, 2022 | 12:58h | UTC
RCT | Comparison of acupuncture vs. sham acupuncture in the treatment of aromatase inhibitor–related joint pain.
15 Nov, 2022 | 12:47h | UTC
Commentary on Twitter
https://twitter.com/JAMANetworkOpen/status/1591113526222913538
Cohort Study | Association of Taxane type with chemotherapy-induced peripheral neuropathy in patients with breast cancer.
4 Nov, 2022 | 13:15h | UTC
Single-arm P2 study | Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy.
2 Nov, 2022 | 14:23h | UTCEliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: Elimination of Surgery Explored for Selected Breast Cancer Patients – HealthDay
Commentary on Twitter
Online first: #Eliminating breast #surgery for invasive #breastcancer in exceptional #responders to #neoadjuvant systemic #therapy: a multicentre, single-arm, phase 2 trial https://t.co/lxZa62zFZT pic.twitter.com/TS1dKqFhF1
— The Lancet Oncology (@TheLancetOncol) October 26, 2022
Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.
31 Oct, 2022 | 13:50h | UTC
Nonsurgical options for risk reduction of contralateral breast cancer in BRCA mutation carriers with early breast cancer.
31 Oct, 2022 | 13:41h | UTCNonsurgical Options for Risk Reduction of Contralateral Breast Cancer in BRCA Mutation Carriers With Early-Stage Breast Cancer – Journal of Clinical Oncology (free for a limited period)